The Filing Desk

Harvard Bioscience vs Quanterix

Harvard Bioscience HBIO · Quanterix QTRX · Life Sciences Tools & Services

Quanterix reported revenue of $139 million in fiscal 2025, 1.6 times Harvard Bioscience's $86 million in fiscal 2025. Harvard Bioscience's revenue fell 8.1% in its latest year, and Quanterix's grew 1.1%. Harvard Bioscience had an operating margin of -56.1%, against -90.4% at Quanterix. Free cash flow was $5 million at Harvard Bioscience and −$80 million at Quanterix.

Side by side

Harvard BioscienceQuanterix
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$86M$139M
Revenue growth−8.1%1.1%
Revenue growth a year, last 5 years−3.3%10.0%
Gross margin57.7%46.8%
Operating margin−56.1%−90.4%
Net margin−65.5%−77.1%
Free cash flow$5M−$80M
Free cash flow margin6.3%−57.5%
Return on capital−56.0%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.0%11.1%
Last close$8.68$2.03
P/E at the last close——
Insider trades, last 12 monthsbought $202,354, sold $0bought $296,049, sold $0
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Harvard BioscienceQuanterix
Operating margin
Percent of revenue
Harvard BioscienceQuanterix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Harvard BioscienceQuanterix

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Harvard Bioscience and Quanterix pages.